Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Collaborative Groups / Breast and Gynecologic Cancers Research Group / FDA approved autoantibody panel identified as potential serum biomarker for triple-negative breast cancer

FDA approved autoantibody panel identified as potential serum biomarker for triple-negative breast cancer

OVA1 for Ovarian Cancer

Click here to visit the biomarker database for more information on OVA1.

2016 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take on a date and location to be determined.